A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial2022 · 132 citations
2. 2Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration2020 · 52 citations
3. 3NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances2018 · 576 citations
4. 4Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF192014 · 179 citations
5. 5Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis2018 · 373 citations